Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
5.12
+0.40 (8.47%)
At close: Nov 25, 2025, 4:00 PM EST
5.70
+0.58 (11.33%)
Pre-market: Nov 26, 2025, 8:15 AM EST
Verrica Pharmaceuticals Revenue
Verrica Pharmaceuticals had revenue of $14.34M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $30.83M, up 234.73% year-over-year. In the year 2024, Verrica Pharmaceuticals had annual revenue of $7.57M with 47.66% growth.
Revenue (ttm)
$30.83M
Revenue Growth
+234.73%
P/S Ratio
1.46
Revenue / Employee
$434,211
Employees
71
Market Cap
48.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.57M | 2.44M | 47.66% |
| Dec 31, 2023 | 5.12M | -3.91M | -43.27% |
| Dec 31, 2022 | 9.03M | -2.97M | -24.73% |
| Dec 31, 2021 | 12.00M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VRCA News
- 2 days ago - Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway - GlobeNewsWire
- 8 days ago - Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 16 days ago - Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 4 weeks ago - Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 5 weeks ago - Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union - GlobeNewsWire
- 7 weeks ago - Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum - GlobeNewsWire